Vaxart's oral RSV candidate protects in preclinical challenge

While working to catch up with other vaccine developers in the race for a respiratory syncytial virus (RSV) vaccine, San Francisco-based Vaxart this week unveiled data demonstrating its candidate's ability to create a "substantial" immune response in a preclinical challenge model.

Celldex's brain cancer vaccine Rintega shows survival advantage at 2-year mark

Celldex touted what it called the "consistent, impressive story" of its cancer vaccine Rintega this week as it released positive long-term survival data.

Scripps scientists ID weakness-attacking antibodies in pursuit of HIV vaccine

A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.

MSF launches vaccine pricing petition aimed at Pfizer, GSK

Médecins Sans Frontières, a global charity and frequent pharma critic, has initiated a worldwide petition calling for Pfizer and GlaxoSmithKline to reduce the prices of their pneumonia vaccines to $5 per child--for all three doses--in emerging markets and for humanitarian organizations.

WHO meeting could change strain selection for flu vaccines

Health officials and experts will discuss ways to improve global surveillance of the flu and expedite the selection process for which flu strains to include in the vaccine each year.

GlaxoSmithKline Ebola vaccine shows safety in PhI

GlaxoSmithKline's experimental Ebola jab, which was taken to Phase I in the U.S. and Mali last October, was well-tolerated and elicited strong immune responses in adults.

Researchers tout vaccine's potential to lower cholesterol

Early cost projections for the newly approved cholesterol-lowering PCSK9 meds from Sanofi/Regeneron and Amgen have predicted the meds will cost providers anywhere between $15 billion and an astronomical $150 billion each year. However, researchers say they are working on a vaccine with the potential to lower high cholesterol in a more cost-effective way.

FDA panel to examine 'maternal vaccines' to protect infants

Several manufacturers are already developing vaccines to protect infants via maternal immunization, but the potential of such vaccines has "yet to be fully realized." This Friday, an FDA advisory panel will examine the development and licensing of these "maternal vaccines," MedPage Today reported.

GeneOne, Inovio's MERS vaccine enters PhI at Walter Reed

With an eye on an "emergent global health concern," GeneOne Life Science teamed up with the Walter Reed Army Institute of Research this week to usher its vaccine for Middle East respiratory syndrome (MERS) into a first-in-human trial at the institute.

James Cook University researcher wins $2M Gates grant for malaria vaccine development

Louis Schofield, director of the Australian Institute of Tropical Health and Medicine at James Cook University, received a grant from the Bill & Melinda Gates Foundation worth AU$2.8 million to pursue preclinical development of a malaria vaccine.

MenAfriVac succeeds in sub-Saharan Africa, but the fight isn't over yet

Five years after the affordable meningitis jab, MenAfriVac, was introduced in Africa's "meningitis belt," it has nearly eliminated the disease on the continent, the World Health Organization and PATH announced on Tuesday. But scientists are warning against overconfidence, predicting that meningitis could bounce back if immunization efforts let up now.

Novavax kicks off PhIII trial for its RSV vaccine

Barely a month after reporting promising Phase II results for its respiratory syncytial virus (RSV) jab and netting an $89 million Gates Foundation grant, Gaithersburg, MD-based Novavax is going full steam ahead, initiating a Phase III trial for its RSV candidate.

Sanofi unveils its work on improving flu vaccines

This week at the World Vaccines Congress in Spain, Sanofi Pasteur announced that in collaboration with the University of Georgia it has developed a candidate flu vaccine through genetic sequencing of many flu viruses. The vaccine, dubbed Cobra, is designed to protect against multiple strains over several years using common sequences the strains share.

EMA safety review raises no issues with HPV vaccines from Merck, GSK

For years, Merck and GlaxoSmithKline have battled safety worries and other stigmas with their HPV vaccines. But this week, the companies received a piece of positive news from the European Medicines Agency, which reported that a committee found no link between the shots and two rare conditions it had been studying.

Takeda, Hilleman eye low-cost vaccine space

Takeda wants to join the likes of India's Hilleman Labs and Serum Institute and grab a piece of the low-cost vaccine pie. The Japanese pharma closed a €3 million ($3.3 million) equity investment in Belgium-based Univercell to use the latter's technology with vaccines in Takeda's pipeline to produce affordable vaccines for developing countries.

Sanofi expects first dengue vaccine license in Q4

After Sanofi's sizable investment into its dengue vaccine program, new company CEO Olivier Brandicourt said on the Q3 call that the French pharma expects its first license to market the vaccine by year end.

Pfizer teams up with the Biovac Institute to produce Prevenar 13 in South Africa

In South Africa, 40% of the national budget for vaccines is used to import Pfizer's Prevenar 13, according to Science and Technology Minister Naledi Pandor. To ease this burden, Pfizer and South Africa's Biovac Institute are entering a 5-year partnership to produce the vaccine domestically, Reuters reported.

GSK's vaccine unit sees revenue, profit jump in Q3

After struggling out of the gate with Novartis' vaccines in hand, GlaxoSmithKline's vaccines unit turned its fortune in the third quarter and was able to deliver considerable increases in sales and profits.

European Commission launches €23M HIV vaccine research initiative

Seeking to throw support into a field that has seen recent scientific advancements, the European Commission is stepping up with funding to form the European AIDS Vaccine Initiative. The effort will set out to develop protective and therapeutic HIV vaccines by bringing together experts from 22 institutions, both public and private.

Bavarian Nordic announces PhI data for new cancer vaccine candidate

Bavarian Nordic makes most of its money from its smallpox business, but it is working to expand its reach with moves in the cancer vaccine arena. Toward that end, the Danish company announced on Tuesday the results from a National Cancer Institute-sponsored Phase I study of its new cancer vaccine candidate, MVA-BN Brachyury.